Oncimmune LLC
8960 Commerce Drive Building #6
De Soto
Kansas
66018
United States
Tel: 888-583-9030
Website: http://www.oncimmune.com/
23 articles about Oncimmune LLC
-
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
5/22/2023
Freenome announced it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.
-
Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer
9/9/2019
Oncimmune Holdings plc welcomes the presentation of data by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.
-
Biodesix to Acquire Oncimmune in the United States
6/28/2019
Acquisition of US Laboratory and Lung Nodule Malignancy Risk Test
-
Oncimmune Signs Agreement with America’s Choice Provider Network to Expand Access to its Blood Tests for the Early Detection of Lung and Liver Cancers
12/20/2018
Oncimmune Holdings plc, announced that it has entered into an agreement with America’s Choice Provider Network (ACPN) to expand access to Oncimmune’s simple and affordable blood tests, EarlyCDT®—Lung and EarlyCDT®—Liver.
-
Oncimmune Demonstrates Clinical Utility of Early Lung Cancer Detection Test at IASLC World Conference on Lung Cancer
9/25/2018
Use of EarlyCDT®-Lung results in a high positive predictive value for detecting malignancy in indeterminate pulmonary nodules, with a low resection rate for benign disease
-
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
12/5/2017
In the Phase 1 clinical trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing prostate specific antigen (PSA) were treated with six intradermal injections of ProscaVax.
-
Oncimmune: Launch of 'Finger Stick' Sample Collection for EarlyCDT-Lung
11/9/2017
Simplified blood sample collection procedure introduces ease of use and quicker results.
-
Oncimmune LLC CMO Producing First Batch Of Tretinoin For Acute Promyelocytic Leukemia
10/2/2017
-
Oncimmune LLC Signs Agreement With Accu Reference
3/18/2016
-
Oncimmune LLC Signs Agreement With Leading Provider Of Preventative Health Screenings
3/3/2016
-
Oncimmune LLC Appoints Greg Stanley As President Of Commercial Operations
1/20/2016
-
Oncimmune LLC Appoints Dr James Jett, World Recognised Lung Cancer Specialist, As Chief Medical Officer
11/19/2015
-
Oncimmune LLC Acquires Dedicated Commercial Testing Facility For EarlyCDT-Lung From Health Diagnostic Laboratory
9/24/2015
-
Oncimmune LLC Appoints Meinhard Schmidt As Chairman
9/14/2015
-
NetScientific’s Subsidiary, Glycotest Begins A New Research Collaboration With Oncimmune LLC
10/3/2014
-
Health Diagnostic Laboratory Inc. Acquires Exclusive U.S. License for Early Lung Cancer Detection Test From Oncimmune Ltd.
10/22/2013
-
Oncimmune LLC Release: National Jewish Health, the Nation's Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
5/1/2012
-
Oncimmune LLC Release: Major Lung Cancer Screening Trial Announced by the NHS in Scotland Using an Innovative Blood Test, EarlyCDT(R) -- Lung
3/22/2012
-
Oncimmune LLC Release: Abstracts Reporting EarlyCDT(TM)-Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection of Solid Tumor Lung Cancers
5/12/2011
-
Oncimmune LLC: Abstracts Reporting EarlyCDT(TM) Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection of Solid Tumor Lung Cancers
11/1/2010